Medical News

[ Ultra-Long-Acting Insulin Degludec, Two Phase 3 Studies Published ]

Ultra-Long-Acting Insulin Degludec, Two Phase 3 Studies Published

Two Phase III studies, published in The Lancet, reveal that ultra-long-acting insulin degludec considerably reduced rates of nocturnal hypoglycemia in patients with type 1 and type 2 diabetes by 25%, compared to insulin glargine. Insulin degludec is an investigational compound developed by Novo Nordisk. 1, 635 individuals with diabetes were enrolled to participate in the trials in order to examine insulin degludec, compared to insulin glargine, in a basal-bolus regimen. In both studies, researchers adjusted patient insulin doses systematically in order to allow them to achieve a targeted fasting glucose level. Due to this, participants in both studies successfully achieved similar improvements in sugar control. This allowed the researchers to closely determine disparity in hypoglycemia rates.

Maxonidine, A Second-Generation Drug Used For Hypertension Aids Heart Function Independent Of Blood Pressure

Heart failure is the most common cause of death throughout the world, typically the result of chronic high blood pressure, also known as hypertension. As a result, research efforts have focused on an array of approaches aimed at preventing and treating high blood pressure. Recently, Japanese researchers examined the utility of an anti-hypertensive drug, moxonidine, which acts on the imidazoline receptors in the cardiovascular center of the brainstem. They found, using an animal model, that the drug can improve heart function and survival independent of its effect on blood pressure. They also found the drug had a favorable effect on oxidative stress, which is related to insulin resistance, the underlying abnormality in diabetes, which is common in people with heart failure. An abstract presentation about the findings was offered at the meeting Experimental Biology 2012, being held April 21-25 at the San Diego Convention Center.

Transplanting Gut Microbiota May Protect From Diabetes And Fatty Liver Disease

An exciting presentation at the International Liver Congress (TM) 2012 has revealed that gut microbiota play a contributing role in the development of diabetes and non-alcoholic fatty liver disease (NAFLD) independent of obesity. The French researchers underline that gut microbiota transplantation, i.e. grafting new microbiota from a healthy donor's faecal material and transplanting it into the colon of a diseased recipient, can potentially prevent diabetes and NAFLD. In a 16-week animal study, the researchers transplanted gut microbiota into two groups of germ free mice. One set of microbiota was grafted from donor mice with symptoms of insulin resistance and liver steatosis (responders), whilst the other transplants were obtained from normal mice (non responders). The donor mice were selected based on their response to being fed a high fat diet.

Insulin Usually Better Than Oral Drugs For Type 2 Diabetes

According to a study published in, the combination of insulin and metformin may not benefit individuals with type 2 diabetes. Although the combination results in less weight gain, improved blood glucose control and less need for insulin, the researchers state that further research is required in order to provide solid evidence regarding the benefits and harms, as well as the risks of premature death. The study was conducted by researchers from the Copenhagen Trial Unit, Steno Hospital and the Copenhagen University Hospital. At present, guidelines recommend metformin, an oral blood glucose reducing medication, for type 2 diabetics starting insulin treatment. The researchers examined 2, 217 individuals aged 18+ with type 2 diabetes. Among the trials examined, the team found insufficient reports of important patient outcomes, such as total mortality and death from heart disease.

Anti-Diabetic Substance Found In Liquorice Root

It provides the raw material for liquorice candy, calms the stomach and alleviates diseases of the airways: liquorice root. Chosen as the "Medicinal plant 2012", the root has been treasured in traditional healing since ancient times. Researchers at the Max Planck Institute for Molecular Genetics in Berlin have now discovered that liquorice root also contains substances with an anti-diabetic effect. These amorfrutins not only reduce blood sugar, they are also anti-inflammatory and are very well tolerated. Thus, they may be suitable for use in the treatment of complex metabolic disorders. Natural substances have a surprising and often largely unexploited potential in the prevention and treatment of common diseases. For example, liquorice root Glycyrrhiza contains different substances that help to alleviate disorders of the airways and digestive system.

Medical News © Nanda
Designer Damodar